Wave Life Sciences' Weight-Loss Drug: Early Win or Flop?
Business & Finance News Today | 2 Min News | The Daily News Now! · The Daily News Now!
Audio is streamed directly from the publisher (api.fastcast.ai) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Wave Life Sciences WVE-007 shows promise in targeting visceral fat, reducing total fat by five percent and visceral fat by fourteen percent, despite a one percent body weight drop in phase one trials. Despite market panic, the drugs potential as a niche player in healthier weight loss is hinted at, with phase two and three trials set to confirm or expose flaws. For risk-tolerant investors, this dip could be an opportunity to eye small stakes in the anti-obesity play.
Support the show:
Get a discount at https://solipillow.com/discount/dnn.
Advertise on DNN:
[email protected]
This is an automated, high-level news summary based on public reporting.
Report issues to [email protected].
View sources & latest updates:
https://sources.thednn.ai/7fb1fb295f14de97